204 related articles for article (PubMed ID: 12796362)
21. Imbalanced expression of functionally different WT1 isoforms may contribute to sporadic unilateral Wilms' tumor.
Liu JJ; Wang ZY; Deuel TF; Xu YH
Biochem Biophys Res Commun; 1999 Jan; 254(1):197-9. PubMed ID: 9920757
[TBL] [Abstract][Full Text] [Related]
22. Expression and prognostic value of Wilms' tumor 1 and early growth response 1 proteins in nephroblastoma.
Ghanem MA; Van der Kwast TH; Den Hollander JC; Sudaryo MK; Oomen MH; Noordzij MA; Van den Heuvel MM; Nassef SM; Nijman RM; Van Steenbrugge GJ
Clin Cancer Res; 2000 Nov; 6(11):4265-71. PubMed ID: 11106242
[TBL] [Abstract][Full Text] [Related]
23. Genome-wide loss of heterozygosity analysis of WT1-wild-type and WT1-mutant Wilms tumors.
Ruteshouser EC; Hendrickson BW; Colella S; Krahe R; Pinto L; Huff V
Genes Chromosomes Cancer; 2005 Jun; 43(2):172-80. PubMed ID: 15761866
[TBL] [Abstract][Full Text] [Related]
24. Decreased E-cadherin expression correlates with higher stage of Wilms' tumors.
Safford SD; Freemerman AJ; Langdon S; Bentley R; Goyeau D; Grundy PE; Skinner MA
J Pediatr Surg; 2005 Feb; 40(2):341-8. PubMed ID: 15750927
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic utility of WT1 immunostaining in ovarian sertoli cell tumor.
Zhao C; Bratthauer GL; Barner R; Vang R
Am J Surg Pathol; 2007 Sep; 31(9):1378-86. PubMed ID: 17721194
[TBL] [Abstract][Full Text] [Related]
26. Gene expression profiling of favorable histology Wilms tumors and its correlation with clinical features.
Takahashi M; Yang XJ; Lavery TT; Furge KA; Williams BO; Tretiakova M; Montag A; Vogelzang NJ; Re GG; Garvin AJ; Söderhäll S; Kagawa S; Hazel-Martin D; Nordenskjold A; Teh BT
Cancer Res; 2002 Nov; 62(22):6598-605. PubMed ID: 12438255
[TBL] [Abstract][Full Text] [Related]
27. Correlation of germ-line mutations and two-hit inactivation of the WT1 gene with Wilms tumors of stromal-predominant histology.
Schumacher V; Schneider S; Figge A; Wildhardt G; Harms D; Schmidt D; Weirich A; Ludwig R; Royer-Pokora B
Proc Natl Acad Sci U S A; 1997 Apr; 94(8):3972-7. PubMed ID: 9108089
[TBL] [Abstract][Full Text] [Related]
28. RNA expression of the WT1 gene in Wilms' tumors in relation to histology.
Miwa H; Tomlinson GE; Timmons CF; Huff V; Cohn SL; Strong LC; Saunders GF
J Natl Cancer Inst; 1992 Feb; 84(3):181-7. PubMed ID: 1311774
[TBL] [Abstract][Full Text] [Related]
29. Transcriptional regulation by the Wilms' tumour suppressor protein WT1.
Wagner KJ; Roberts SG
Biochem Soc Trans; 2004 Dec; 32(Pt 6):932-5. PubMed ID: 15506928
[TBL] [Abstract][Full Text] [Related]
30. The expression pattern of Wilms' tumour gene (WT1) product in normal tissues and paediatric renal tumours.
Ramani P; Cowell JK
J Pathol; 1996 Jun; 179(2):162-8. PubMed ID: 8758208
[TBL] [Abstract][Full Text] [Related]
31. p53 expression in Wilms' tumor: a possible role as prognostic factor.
Beniers AJ; Efferth T; Füzesi L; Granzen B; Mertens R; Jakse G
Int J Oncol; 2001 Jan; 18(1):133-9. PubMed ID: 11115550
[TBL] [Abstract][Full Text] [Related]
32. Canonical WNT signalling determines lineage specificity in Wilms tumour.
Fukuzawa R; Anaka MR; Weeks RJ; Morison IM; Reeve AE
Oncogene; 2009 Feb; 28(8):1063-75. PubMed ID: 19137020
[TBL] [Abstract][Full Text] [Related]
33. Comparative in situ hybridization analysis of PAX2, PAX8, and WT1 gene transcription in human fetal kidney and Wilms' tumors.
Eccles MR; Yun K; Reeve AE; Fidler AE
Am J Pathol; 1995 Jan; 146(1):40-5. PubMed ID: 7856737
[TBL] [Abstract][Full Text] [Related]
34. Codon 45 of the beta-catenin gene, a specific mutational target site of Wilms' tumor.
Kusafuka T; Miao J; Kuroda S; Udatsu Y; Yoneda A
Int J Mol Med; 2002 Oct; 10(4):395-9. PubMed ID: 12239584
[TBL] [Abstract][Full Text] [Related]
35. Responsiveness of chemotherapy based on the histological type and Wilms' tumor suppressor gene mutation in bilateral Wilms' tumor.
Shibata R; Takata A; Hashiguchi A; Umezawa A; Yamada T; Hata J
Pathol Int; 2003 Apr; 53(4):214-20. PubMed ID: 12675764
[TBL] [Abstract][Full Text] [Related]
36. Bilateral Wilms tumor and early presentation in pediatric patients is associated with the truncation of the Wilms tumor 1 protein.
Hu M; Fletcher J; McCahon E; Catchpoole D; Zhang GY; Wang YM; Algar EM; Alexander SI
J Pediatr; 2013 Jul; 163(1):224-9. PubMed ID: 23403252
[TBL] [Abstract][Full Text] [Related]
37. WT1 splicing alterations in Wilms' tumors.
Baudry D; Hamelin M; Cabanis MO; Fournet JC; Tournade MF; Sarnacki S; Junien C; Jeanpierre C
Clin Cancer Res; 2000 Oct; 6(10):3957-65. PubMed ID: 11051244
[TBL] [Abstract][Full Text] [Related]
38. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.
Reinhard H; Semler O; Bürger D; Bode U; Flentje M; Göbel U; Gutjahr P; Leuschner I; Maass E; Niggli F; Scheel-Walter HG; Stöckle M; Thüroff JW; Tröger J; Weirich A; von Schweinitz D; Zoubek A; Graf N
Klin Padiatr; 2004; 216(3):132-40. PubMed ID: 15175957
[TBL] [Abstract][Full Text] [Related]
39. The third zinc finger of the WT1 gene is mutated in Wilms' tumour but not in a broad range of other urogenital tumours.
Quek HH; Chow VT; Tock EP
Anticancer Res; 1993; 13(5A):1575-80. PubMed ID: 8239537
[TBL] [Abstract][Full Text] [Related]
40. WTX inactivation is a frequent, but late event in Wilms tumors without apparent clinical impact.
Wegert J; Wittmann S; Leuschner I; Geissinger E; Graf N; Gessler M
Genes Chromosomes Cancer; 2009 Dec; 48(12):1102-11. PubMed ID: 19760609
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
